Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
about
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerA phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceLinking signaling pathways to transcriptional programs in breast cancer.Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.Novel agents that downregulate EGFR, HER2, and HER3 in parallelDeciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerMEK inhibition increases lapatinib sensitivity via modulation of FOXM1New developments in the treatment of HER2-positive breast cancerERRα mediates metabolic adaptations driving lapatinib resistance in breast cancerMechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines.The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 genePI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
P2860
Q26753162-50712657-D8DD-42B7-B98D-032E49680FFCQ33410791-29D8498E-84D0-461A-B139-4F1D5CB6D478Q34355748-9EF65354-27DF-4EA3-8F14-3761511DAF5AQ34439395-C1C4D5B2-C6FE-48D8-BCE3-4591C75C8ECCQ35803226-1D5826D2-C14E-4BFB-A605-627C6AA49CF0Q35833034-7A3D1B00-1217-466C-9485-EBDD31175711Q36102124-A9418CC5-EABD-4D71-B7AD-A6864E8E783EQ36440214-23CAB14E-6BD0-45B1-AF2C-6097E65A93B8Q36833298-5FC52FCD-2C57-4867-A39E-3A2BC8A01503Q37016382-8BCB0E35-CD8F-4366-8FBB-82692BA19370Q37096669-5E3D70B4-C1CE-492B-AC64-670B2E4247BEQ37263096-40CA3C5D-747E-4F8A-832F-AC18EC961ECEQ37605126-C1789A56-062C-4EA8-B307-B39576AD7845Q38259259-1283B968-89A5-4CC8-9A4D-8D0F323EB281Q38301236-B239CE38-703D-4CFE-9813-52D4B3C1DA15Q38812867-ACAD8974-EADC-4A9D-AF47-B9707A85119BQ39254901-57D7B692-06C7-49A9-95B5-0EDF838FF2A7Q39520887-27C5194E-6781-434A-A152-C3714DD6DA0FQ48095126-7DEF2F67-9F4C-4365-B0C7-79FF73917A06Q51023478-2FD0B42B-0E74-4C40-BA2E-F6E6642B27D0
P2860
Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacologic inhibition of mT ...... rimary trastuzumab resistance.
@ast
Pharmacologic inhibition of mT ...... rimary trastuzumab resistance.
@en
type
label
Pharmacologic inhibition of mT ...... rimary trastuzumab resistance.
@ast
Pharmacologic inhibition of mT ...... rimary trastuzumab resistance.
@en
prefLabel
Pharmacologic inhibition of mT ...... rimary trastuzumab resistance.
@ast
Pharmacologic inhibition of mT ...... rimary trastuzumab resistance.
@en
P2093
P2860
P1476
Pharmacologic inhibition of mT ...... rimary trastuzumab resistance.
@en
P2093
Rita Nahta
Ruth M O'Regan
Samuel L M Arnold
Sylvia S Gayle
P2860
P304
P356
10.2174/187152012799015002
P577
2012-02-01T00:00:00Z